Publicaciones en colaboración con investigadores/as de Hospital Universitario La Paz (12)

2020

  1. SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019)

    Clinical and Translational Oncology, Vol. 22, Núm. 2, pp. 236-244

2019

  1. Treatment and outcome of patients with stage is testicular cancer: A retrospective study from the Spanish germ cell cancer group

    Journal of Urology, Vol. 202, Núm. 4, pp. 742-747

2017

  1. Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer

    European Urology Focus, Vol. 3, Núm. 2-3, pp. 280-286

  2. Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain

    Clinical and Translational Oncology, Vol. 19, Núm. 4, pp. 498-507

2016

  1. Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH

    Medicina Clinica, Vol. 146, Núm. 11, pp. 511.e1-511.e22

  2. Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?

    Clinical and Translational Oncology, Vol. 18, Núm. 11, pp. 1072-1081

2015

  1. Clinical guideline SEOM: hepatocellular carcinoma

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 988-995

  2. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy

    Molecular Diagnosis and Therapy, Vol. 19, Núm. 6, pp. 397-408

2014

  1. Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer

    Clinical and Translational Oncology, Vol. 16, Núm. 11, pp. 942-953

2011

  1. Irinotecan-cetuximab-bevacizumab as a salvage treatment in heavily pretreated metastatic colorectal cancer patients: A retrospective observational study

    Chemotherapy, Vol. 57, Núm. 2, pp. 138-144

2010

  1. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Results from the National Cancer Registry of Spain (RGETNE)

    Annals of Oncology, Vol. 21, Núm. 9, pp. 1794-1803

2009

  1. Consensus on the treatment of pancreatic cancer in Spain

    Clinical and Translational Oncology, Vol. 11, Núm. 5, pp. 290-301